Related references
Note: Only part of the references are listed.Cytotoxic Properties of Sunitinib and Sorafenib on Human Corneal Epithelial Cells
Tarek Bayyoud et al.
CURRENT EYE RESEARCH (2014)
Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
M. Dror Michaelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate
Alejandro S. Godoy et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design
Javier Blanc et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2013)
Anti-angiogenic therapies in prostate cancer
Jose Maria Martinez-Jabaloyas et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue
Wei Luo et al.
ONCOTARGET (2013)
State of the art paper Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
Magdalena Zaborowska et al.
Archives of Medical Science (2012)
Angiogenesis in prostate cancer: onset, progression and imaging
Giovanna Russo et al.
BJU INTERNATIONAL (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
In Vivo, In Vitro Toxicity and In Vitro Angiogenic Inhibition of Sunitinib Malate
Eduardo Dib et al.
CURRENT EYE RESEARCH (2012)
Targeting angiogenesis for the treatment of prostate cancer
Emmanuel S. Antonarakis et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
Emma K. Beardsley et al.
INVESTIGATIONAL NEW DRUGS (2012)
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells
P. Kharaziha et al.
CELL DEATH & DISEASE (2012)
IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
Michael S. Anglesio et al.
CLINICAL CANCER RESEARCH (2011)
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients
Daniel Castellano et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Tumor exploits alternative strategies to achieve vascularization
Benedetta Bussolati et al.
FASEB JOURNAL (2011)
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
G. Sonpavde et al.
ANNALS OF ONCOLOGY (2010)
Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors
M. B. Nilsson et al.
ONCOGENE (2010)
Phase II study of sunitinib in men with advanced prostate cancer
M. Dror Michaelson et al.
ANNALS OF ONCOLOGY (2009)
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
Jeanny B. Aragon-Ching et al.
BJU INTERNATIONAL (2009)
Tumor endothelial cells have features of adult stem cells
Andrew C. Dudley et al.
CELL CYCLE (2009)
Human Hepatocellular Carcinoma Tumor-derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells
Yu-Quan Xiong et al.
CLINICAL CANCER RESEARCH (2009)
Calcification of multipotent prostate tumor endothelium
Andrew C. Dudley et al.
CANCER CELL (2008)
Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies
Kyoko Hida et al.
CANCER SCIENCE (2008)
A phase II clinical trial of sorafenib in androgen-independent prostate cancer
William L. Dahut et al.
CLINICAL CANCER RESEARCH (2008)
Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell
Alejandro Godoy et al.
ENDOCRINOLOGY (2008)
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S. Steinbild et al.
BRITISH JOURNAL OF CANCER (2007)
Endothelial progenitor cell-derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA
Maria Chiara Deregibus et al.
BLOOD (2007)
Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function
Gabriel Bidaux et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature
Judy R. van Beijnum et al.
BLOOD (2006)
The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway
Benedetta Bussolati et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2006)
Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures
B Bussolati et al.
EXPERIMENTAL CELL RESEARCH (2006)
Tumor-associated endothelial cells display GSTP1 and RARβ2 promoter methylation in human prostate cancer
AC Grover et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2006)
Expression of Pax2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis
V Fonsato et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis
T Matsumoto et al.
EMBO JOURNAL (2005)
Canonical transient receptor potential 1 plays a role in basic fibroblast growth factor (bFGF)/FGF receptor-1-induced Ca2+ entry and embryonic rat neural stem cell proliferation
AF Pla et al.
JOURNAL OF NEUROSCIENCE (2005)
Cellular abnormalities of blood vessels as targets in cancer
P Baluk et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2005)
Tumor-associated endothelial cells with cytogenetic abnormalities
K Hida et al.
CANCER RESEARCH (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Share Paper
